Intravitreal Bevacizumab (Avastin) for Myopic Choroidal Neovascularization. Six-Month Results of a Prospective Pilot Study

Ophthalmology

Volumn 114, Issue 12, 2007, Pages

  Chan, Wai Man ^a,b,c   Lai, Timothy Y Y ^a   Liu, David T L ^b   Lam, Dennis S C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; LEVOFLOXACIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTERVENTION STUDY; MALE; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFRACTION ERROR; RETINA FOVEA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SUBRETINAL NEOVASCULARIZATION; THICKNESS; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY;

EID: 36549066793     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2007.03.043     Document Type: Article

References (33)

1. Avila M.P., Weiter J.J., Jalkh A.E., et al. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 91 (1984) 1573-1581
2. Hampton G.R., Kohen D., and Bird A.C. Visual prognosis of disciform degeneration in myopia. Ophthalmology 90 (1983) 923-926
3. Ohno-Matsui K., Yoshida T., Futagami S., et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol 87 (2003) 570-573
4. Cohen S.Y., Laroche A., Leguen Y., et al. Etiology of choroidal neovascularization in young patients. Ophthalmology 103 (1996) 1241-1244
5. Tabandeh H., Flynn Jr. H.W., Scott I.U., et al. Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 106 (1999) 2063-2067
6. Yoshida T., Ohno-Matsui K., Ohtake Y., et al. Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups. Ophthalmology 109 (2002) 712-719
7. Chan W.M., Ohji M., Lai T.Y., et al. Choroidal neovascularisation in pathological myopia: an update in management. Br J Ophthalmol 89 (2005) 1522-1528
8. Ergun E., Heinzl H., and Stur M. Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia. Am J Ophthalmol 138 (2004) 434-438
9. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 108 (2001) 841-852
10. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology 110 (2003) 667-673
11. Montero J.A., and Ruiz-Moreno J.M. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol 87 (2003) 173-176
12. Lam D.S., Chan W.M., Liu D.T., et al. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up. Br J Ophthalmol 88 (2004) 1315-1319
13. Lam D.S., Liu D.T., Fan D.S., et al. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia: 1-year results of a prospective series. Eye 19 (2005) 834-840
14. Gelisken F., Inhoffen W., Hermann A., et al. Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 242 (2004) 926-930
15. Schnurrbusch U.E., Jochmann C., Wiedemann P., and Wolf S. Quantitative assessment of the long-term effect of photodynamic therapy in patients with pathologic myopia. Graefes Arch Clin Exp Ophthalmol 243 (2005) 829-833
16. Degenring R.F., and Jonas J.B. Photodynamic therapy in combination with intravitreal triamcinolone for myopic choroidal neovascularization. [letter]. Acta Ophthalmol Scand 83 (2005) 621
17. Chan W.M., Lai T.Y., Wong A.L., et al. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol 91 (2007) 174-179
18. Nguyen Q.D., Shah S., Tatlipinar S., et al. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. [letter]. Br J Ophthalmol 89 (2005) 1368-1370
19. Rosenfeld P.J., Moshfeghi A.A., and Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36 (2005) 331-335
20. Avery R.L., Pieramici D.J., Rabena M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 363-372
21. Spaide R.F., Laud K., Fine H.F., et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26 (2006) 383-390
22. Rich R.M., Rosenfeld P.J., Puliafito C.A., et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26 (2006) 495-511
23. Bashshur Z.F., Bazarbachi A., Schakal A., et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142 (2006) 1-9
24. Yamamoto I., Rogers A.H., Reichel E., et al. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 91 (2007) 157-160
25. Sakaguchi H., Ikuno Y., Gomi F., et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 91 (2007) 161-165
26. Holladay J.T. Proper method for calculating average visual acuity. J Refract Surg 13 (1997) 388-391
27. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
28. Michels S., Rosenfeld P.J., Puliafito C.A., et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. Twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112 (2005) 1035-1047
29. Fung A.E., Rosenfeld P.J., and Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90 (2006) 1344-1349
30. Spitzer M.S., Wallenfels-Thilo B., Sierra A., et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol 90 (2006) 1316-1321
31. Maturi R.K., Bleau L.A., and Wilson D.L. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 26 (2006) 270-274
32. Shahar J., Avery R.L., Heilweil G., et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26 (2006) 262-269
33. Manzano R.P., Peyman G.A., Khan P., and Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26 (2006) 257-261